Primary Renal Cell Carcinoma
RESIRT was the first-in-human trial to assess SIRT for the treatment of primary renal cell carcinoma (RCC). This pilot study of 21 patients demonstrated good tolerability of SIR-Spheres® Y-90 resin microspheres at all dose levels in treating primary tumours in RCC patients otherwise unsuitable for conventional therapy. There was no dose-limiting toxicity and no serious adverse events (SAEs) or SAEs related to SIR-Spheres Y-90 resin microspheres. Best overall tumour responses were partial response (PR) in 1/20 (5%), stable disease (SD) in 18/20 (90%) and pseudoprogressive disease in 1/20 (5%). The RESIRT study suggests that SIRT with SIR-Spheres Y-90 resin microspheres may be a feasible treatment option for RCC patients who are unsuitable for conventional therapy, and further clinical studies are warrantied. 1
1 Clark, W. et al. Society of Interventional Radiology (SIR) 42nd Annual Scientific Meeting, J Vasc Interv Radiol 2017; 28 (Suppl): S164 Abs. 379.